Fosun International (00656.HK) issued a positive profit alert on July 29, 2026, forecasting that its profit attributable to owners of the parent for the first half of 2026 will range from approximately RMB1.5 billion to RMB1.8 billion. This represents a substantial year-on-year increase of approximately 127% to 172% compared to the same period last year. The Board of Directors stated that this surge is primarily driven by the strong resilience demonstrated by its core industries, steady improvements in operational quality, and a significant rise in industrial operation profits.

The company’s fundamentals have remained stable since the beginning of 2026, with its three main segments—Health, Wealth, and Happiness—showing consistent development trends. This performance underscores the effectiveness of Fosun’s strategy to streamline operations and focus on core businesses, while steadily exiting non-core assets. Market analysts note that the group has entered a validation phase for its earnings recovery, laying a solid foundation for long-term profitability.

Segment Performance Highlights

The growth is supported by strong contributions from key subsidiaries across all major business segments:

In the Health segment, Fosun Pharma achieved operating revenue of RMB10.073 billion in the first quarter of 2026, a year-on-year increase of 6.93%. Its net profit attributable to shareholders reached RMB871 million, up 13.87% year-on-year. Excluding non-recurring gains and losses, the net profit increased by 21.96%, indicating strong underlying operational efficiency.

The Wealth segment saw robust activity from both insurance arms. Fosun Insurance Portugal (Fidelidade) maintained strong premium growth momentum in the first half of 2026, with double-digit growth recorded in both its domestic Portuguese and overseas businesses. Meanwhile, Pramerica Fosun Life Insurance achieved a net profit of RMB786 million in the first half of 2026, a figure that already exceeds its net profit for the entire year of 2025.

What the Numbers Show

The data reveals a clear acceleration in profitability across diverse sectors, suggesting that the cost-cutting and strategic refocusing measures initiated by management are yielding tangible results. Notably, two major subsidiaries—Pramerica Fosun Life Insurance and Hainan Mining—generated more profit in the first half of 2026 than they did in the entirety of 2025. This rapid turnaround indicates that the "streamlining operations" strategy is not only stabilizing cash flows but significantly enhancing margin structures in core industrial operations.

Fosun International Limited and its Co-CEOs, Chen Qiyu and Xu Xiaoliang, secured five accolades at the 16th Asian Excellence Award presented by Corporate Governance Asia on June 30, 2026. The Group received the Sustainable Asia Award 2026, Best Environmental Responsibility Award, and Best Corporate Communications Award, while both executives were honored as Asia's Best CEO. These awards recognize the company's operational resilience, ESG performance, and leadership in navigating a complex global business environment in 2025.

Corporate Governance Asia recognized Fosun for maintaining a strong strategic focus on core businesses and advancing the deep integration of ESG into its operations. The organization highlighted the company's progress in green development, biodiversity conservation, and public health. Other award recipients included Sino Land, Sun Hung Kai Properties, Bank of China (Hong Kong), and PetroChina.

ESG Ratings and Climate Targets

Fosun International reported significant upgrades in its sustainability ratings during 2025. The MSCI ESG rating was upgraded to AAA, the highest level, while the Hang Seng Sustainability Rating was maintained at AA-. The company was included in S&P Global's Sustainability Yearbook 2026, ranking among the top 1% in China. Additionally, the FTSE Russell ESG score rose to 4.2, and the company was included in the FTSE4Good Index Series for the fifth consecutive time.

Regarding climate action, Fosun has committed to peaking carbon emissions by 2028 and achieving carbon neutrality by 2050. The Group has set a mid-term target to reduce the intensity of Scope 1 and Scope 2 GHG emissions by 20% by 2034, using 2024 as the base year. This strategy aligns with the 1.5°C temperature control target set in the Paris Agreement.

Innovation and Social Impact

Fosun's Health segment has achieved several breakthroughs, including HANSIZHUANG, the world's first monoclonal antibody targeting PD-1 approved for first-line treatment of extensive-stage small cell lung cancer. HLX22 became the world's first anti-HER2-targeted therapy to receive Orphan Drug Designation approvals from the U.S. FDA and the European Commission for gastric cancer. As of December 31, 2025, Fosun Pharma's independently developed artesunate for injection had saved more than 88 million severe malaria patients worldwide, with over 440 million doses supplied globally.

The Fosun Foundation, established in 2012, manages the company's social responsibility initiatives. The Rural Doctors Program, launched in 2017, has covered 78 counties in 16 provinces, supporting 25,000 rural doctors and benefiting 3 million rural families. In biodiversity conservation, the Sea Turtle Shelter at the Atlantis Sanya aquarium was inaugurated on May 23, 2026, covering 388 square meters to provide rehabilitation and habitat for rescued sea turtles.